{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:23:32Z","timestamp":1790720612831,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,21]]},"DOI":"10.7759\/cureus.15816","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T17:06:48Z","timestamp":1624295208000},"source":"Crossref","is-referenced-by-count":28,"title":["Benzodiazepine Misuse: An Epidemic Within a Pandemic"],"prefix":"10.7759","author":[{"given":"Ashish","family":"Sarangi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayasudha","family":"Gude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Coronavirus disease (COVID-19) pandemic. (2021). https.\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019."},{"key":"ref2","unstructured":"The territorial impact of COVID-19. Managing the crisis across levels of government. (2020). Accessed: November 10, 2020: https:\/\/www.oecd.org\/coronavirus\/policy-responses\/the-territorial-impact-of-covid-19-managing-the-crisis-across-level...."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/da.23077","article-title":"U.S. Census Bureau-assessed prevalence of anxiety and depressive symptoms in 2019 and during the 2020 COVID-19 pandemic","volume":"37","author":"Twenge JM","year":"2020","unstructured":"Twenge JM, Joiner TE. U.S. Census Bureau-assessed prevalence of anxiety and depressive symptoms in 2019 and during the 2020 COVID-19 pandemic. Depress Anxiety. 2020, 37:954-6. 10.1002\/da.23077","journal-title":"Depress Anxiety"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7013e2","article-title":"Symptoms of anxiety or depressive disorder and use of mental health care among adults during the COVID-19 pandemic - United States, August 2020-February 2021","volume":"70","author":"Vahratian A","year":"2021","unstructured":"Vahratian A, Blumberg SJ, Terlizzi EP, Schiller JS. Symptoms of anxiety or depressive disorder and use of mental health care among adults during the COVID-19 pandemic - United States, August 2020-February 2021. MMWR Morb Mortal Wkly Rep. 2021, 70:490-4. 10.15585\/mmwr.mm7013e2","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdaa106","article-title":"Increased generalized anxiety, depression and distress during the COVID-19 pandemic: a cross-sectional study in Germany","volume":"42","author":"B\u00e4uerle A","year":"2020","unstructured":"B\u00e4uerle A, Teufel M, Musche V, et al.. Increased generalized anxiety, depression and distress during the COVID-19 pandemic: a cross-sectional study in Germany. J Public Health (Oxf). 2020, 42:672-8. 10.1093\/pubmed\/fdaa106","journal-title":"J Public Health (Oxf)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2020.05.018","article-title":"The immediate impact of the 2019 novel coronavirus (COVID-19) outbreak on subjective sleep status","volume":"77","author":"Lin LY","year":"2021","unstructured":"Lin LY, Wang J, Ou-Yang XY, et al.. The immediate impact of the 2019 novel coronavirus (COVID-19) outbreak on subjective sleep status. Sleep Med. 2021, 77:348-54. 10.1016\/j.sleep.2020.05.018","journal-title":"Sleep Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12960-020-00544-1","article-title":"The prevalence of stress, anxiety and depression within front-line healthcare workers caring for COVID-19 patients: a systematic review and meta-regression","volume":"18","author":"Salari N","year":"2020","unstructured":"Salari N, Khazaie H, Hosseinian-Far A, et al.. The prevalence of stress, anxiety and depression within front-line healthcare workers caring for COVID-19 patients: a systematic review and meta-regression. Hum Resour Health. 2020, 18:100. 10.1186\/s12960-020-00544-1","journal-title":"Hum Resour Health"},{"key":"ref8","article-title":"Good Chemistry: The Life and Legacy of Valium Inventor Leo Sternbach","author":"Baenninger A","year":"2003","unstructured":"Baenninger A, Silva JA, Hindmarch I, et al.. Good Chemistry: The Life and Legacy of Valium Inventor Leo Sternbach. McGraw-Hill, New York; 2003."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/BF01965860","article-title":"The discovery of librium","volume":"2","author":"Sternbach LH","year":"1972","unstructured":"Sternbach LH. The discovery of librium. Agents Actions. 1972, 2:193-6. 10.1007\/BF01965860","journal-title":"Agents Actions"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1021\/jm00187a001","article-title":"The benzodiazepine story","volume":"22","author":"Sternbach LH","year":"1979","unstructured":"Sternbach LH. The benzodiazepine story. J Med Chem. 1979, 22:1-7. 10.1021\/jm00187a001","journal-title":"J Med Chem"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4140\/TCP.n.2013.538","article-title":"The history of benzodiazepines","volume":"28","author":"Wick JY","year":"2013","unstructured":"Wick JY. The history of benzodiazepines. Consult Pharm. 2013, 28:538-48. 10.4140\/TCP.n.2013.538","journal-title":"Consult Pharm"},{"key":"ref12","article-title":"The historical role of barbiturates in \u201csleep cures\u201d for psychotic and manic disorders","volume":"11","author":"Mu\u00f1oz FL","year":"2004","unstructured":"Mu\u00f1oz FL, Alamo C, Udabe RU, Cuenca E. The historical role of barbiturates in \u201csleep cures\u201d for psychotic and manic disorders. Psiquiatr Biol\u00f3gica. 2004, 11:242-51.","journal-title":"Psiquiatr Biol\u00f3gica"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/01.yco.0000165594.60434.84","article-title":"The diagnosis and management of benzodiazepine dependence","volume":"18","author":"Ashton H","year":"2005","unstructured":"Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry. 2005, 18:249-55. 10.1097\/01.yco.0000165594.60434.84","journal-title":"Curr Opin Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/BF00426784","article-title":"Use of antianxiety agents in anxious outpatients","volume":"58","author":"Rickels K","year":"1978","unstructured":"Rickels K. Use of antianxiety agents in anxious outpatients. Psychopharmacology (Berl). 1978, 58:1-17. 10.1007\/BF00426784","journal-title":"Psychopharmacology (Berl)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/9780470515167.ch64","article-title":"Substance abuse: Sedative, hypnotic, or anxiolytic use disorders","author":"Wesson DR","year":"2008","unstructured":"Wesson DR, Smith DE, Ling W, Sabnani S. Substance abuse: Sedative, hypnotic, or anxiolytic use disorders. Psychiatry. Tasman A, Kay J, Lieberman JA (ed): John Wiley & Sons, Chichester; 2008. 1:1186-1200. 10.1002\/9780470515167.ch64"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.148.2.151","article-title":"The APA Task Force report on benzodiazepine dependence, toxicity, and abuse","volume":"148","author":"Salzman C","year":"1991","unstructured":"Salzman C. The APA Task Force report on benzodiazepine dependence, toxicity, and abuse. Am J Psychiatry. 1991, 148:151-2. 10.1176\/ajp.148.2.151","journal-title":"Am J Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2015_425","article-title":"Benzodiazepines","volume":"34","author":"Nielsen S","year":"2017","unstructured":"Nielsen S. Benzodiazepines. Curr Top Behav Neurosci. 2017, 34:141-59. 10.1007\/7854_2015_425","journal-title":"Curr Top Behav Neurosci"},{"key":"ref18","article-title":"Benzodiazepine pharmacology and central nervous system-mediated effects","volume":"13","author":"Griffin CE 3rd","year":"2013","unstructured":"Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013, 13:214-223.","journal-title":"Ochsner J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2018.12.064","article-title":"Monitoring of five benzodiazepines using a novel polymeric interface prepared by layer by layer strategy","volume":"146","author":"Ashrafi H","year":"2019","unstructured":"Ashrafi H, Mobed A, Hasanzadeh M, Babaie P, Ansarin K. Monitoring of five benzodiazepines using a novel polymeric interface prepared by layer by layer strategy. Microchem. J. 2019, 146:121-125. 10.1016\/j.microc.2018.12.064","journal-title":"Microchem. J"},{"key":"ref20","unstructured":"Well-Known Mechanism Underlies Benzodiazepines' Addictive Properties. (2012). Accessed. April 19, 2012: https:\/\/archives.drugabuse.gov\/news-events\/nida-notes\/2012\/04\/well-known-mechanism-underlies-benzodiazepines-addictiv...."},{"key":"ref21","unstructured":"Benzodiazepines. (2020). Accessed. June 15, 2020: https:\/\/www.dea.gov\/factsheets\/benzodiazepines."},{"key":"ref22","unstructured":"What Are Date Rape Drugs and How Do You Avoid Them?. (2015). Accessed. March 16, 2015: https:\/\/archives.drugabuse.gov\/blog\/post\/what-are-date-rape-drugs-and-how-do-you-avoid-them."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201800321","article-title":"Benzodiazepine use and misuse among adults in the United States","volume":"70","author":"Maust DT","year":"2019","unstructured":"Maust DT, Lin LA, Blow FC. Benzodiazepine use and misuse among adults in the United States. Psychiatr Serv. 2019, 70:97-106. 10.1176\/appi.ps.201800321","journal-title":"Psychiatr Serv"},{"key":"ref24","unstructured":"Center for Behavioral Health Statistics and Quality, 2018b. 2017 National Survey on Drug Use and Health. Detailed Tables. Substance Abuse and Mental Health Services Administration, Rockville, MD. (2018). Accessed: September 7, 2018: https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/cbhsq-reports\/NSDUHDetailedTabs2017\/NSDUHDetailedTabs2017.pdf."},{"key":"ref25","article-title":"Monitoring the future national survey results on drug use 1975-2018: overview, key findings on\r\nadolescent drug use.","author":"Johnston LD","year":"2019","unstructured":"Johnston LD, Miech RA, O'Malley PM, Bachman JG, Schulenberg JE, Patrick ME. Monitoring the future national survey results on drug use 1975-2018: overview, key findings on\r\nadolescent drug use.. Institute for Social Research (ed): University of Michigan, Ann Arbor; 2019."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2016.303061","article-title":"Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013","volume":"106","author":"Bachhuber MA","year":"2016","unstructured":"Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013. Am J Public Health. 2016, 106:686-8. 10.2105\/AJPH.2016.303061","journal-title":"Am J Public Health"},{"key":"ref27","unstructured":"Research suggests benzodiazepine use is high while use disorder rates are low. (2018). Accessed. October 18, 2018: https:\/\/www.drugabuse.gov\/news-events\/science-highlight\/research-suggests-benzodiazepine-use-high-while-use-disorder-...."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.watres.2011.10.056","article-title":"Environmental occurrence, fate and transformation of benzodiazepines in water treatment","volume":"46","author":"Kosjek T","year":"2012","unstructured":"Kosjek T, Perko S, Zupanc M, et al.. Environmental occurrence, fate and transformation of benzodiazepines in water treatment. Water Res. 2012, 46:355-68. 10.1016\/j.watres.2011.10.056","journal-title":"Water Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkw122","article-title":"LC-MS-MS method for analysis of benzodiazepines in wastewater during Football Games IV","volume":"41","author":"Stamper B","year":"2017","unstructured":"Stamper B, Gul W, Godfrey M, Gul SW, ElSohly MA. LC-MS-MS method for analysis of benzodiazepines in wastewater during Football Games IV. J Anal Toxicol. 2017, 41:205-13. 10.1093\/jat\/bkw122","journal-title":"J Anal Toxicol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25051026","article-title":"Selected pharmaceuticals in different aquatic compartments: Part I-source, fate and occurrence","volume":"25","author":"Pereira A","year":"2020","unstructured":"Pereira A, Silva L, Laranjeiro C, Lino C, Pena A. Selected pharmaceuticals in different aquatic compartments: Part I-source, fate and occurrence. Molecules. 2020, 25:1026. 10.3390\/molecules25051026","journal-title":"Molecules"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s11356-018-3556-z","article-title":"Environmental risk assessment of psychoactive drugs in the aquatic environment","volume":"26","author":"Cunha DL","year":"2019","unstructured":"Cunha DL, Mendes MP, Marques M. Environmental risk assessment of psychoactive drugs in the aquatic environment. Environ Sci Pollut Res Int. 2019, 26:78-90. 10.1007\/s11356-018-3556-z","journal-title":"Environ Sci Pollut Res Int"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2020.140697","article-title":"Wastewater-based epidemiology pilot study to examine drug use in the Western United States","volume":"745","author":"Bishop N","year":"2020","unstructured":"Bishop N, Jones-Lepp T, Margetts M, Sykes J, Alvarez D, Keil DE. Wastewater-based epidemiology pilot study to examine drug use in the Western United States. Sci Total Environ. 2020, 745:140697. 10.1016\/j.scitotenv.2020.140697","journal-title":"Sci Total Environ"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1126\/science.1226850","article-title":"Dilute concentrations of a psychiatric drug alter behavior of fish from natural populations","volume":"339","author":"Brodin T","year":"2013","unstructured":"Brodin T, Fick J, Jonsson M, Klaminder J. Dilute concentrations of a psychiatric drug alter behavior of fish from natural populations. Science. 2013, 339:814-5. 10.1126\/science.1226850","journal-title":"Science"},{"key":"ref34","unstructured":"Benzodiazepine Equivalence Table. (2007). Accessed. April 2007: https:\/\/www.benzo.org.uk\/bzequiv.htm."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.7399","article-title":"Patterns in outpatient benzodiazepine prescribing in the United States","volume":"2","author":"Agarwal SD","year":"2019","unstructured":"Agarwal SD, Landon BE. Patterns in outpatient benzodiazepine prescribing in the United States. JAMA Netw Open. 2019, 2:187399. 10.1001\/jamanetworkopen.2018.7399","journal-title":"JAMA Netw Open"},{"key":"ref36","unstructured":"Benzodiazepine Equivalence Chart. http.\/\/www.mental-health-today.com\/rx\/benzo.htm."},{"key":"ref37","unstructured":"Benzodiazepine Equivalency\/Half-Life\/Dose Chart. (2003). Accessed. September 19, 2003: http:\/\/www.bluelight.org\/vb\/threads\/99918-Benzodiazepine-Equivalency-Half-Life-Dose-Chart."},{"key":"ref38","unstructured":"Benzodiazepine Dose Conversions (oral). https.\/\/globalrph.com\/medcalcs\/benzodiazepine-converter-dosage-conversions\/."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref40","article-title":"Pharmacological Treatment of Mental Disorders in Primary Health Care","author":"Barbui C","year":"2009","unstructured":"Barbui C, Cipriani A, Saxena S. Pharmacological Treatment of Mental Disorders in Primary Health Care. World Health Organization, Geneva; 2009."},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2020.05.006","article-title":"Psychopharmacology of COVID-19","volume":"61","author":"Bilbul M","year":"2020","unstructured":"Bilbul M, Paparone P, Kim AM, et al.. Psychopharmacology of COVID-19. Psychosomatics. 2020, 61:411-427. 10.1016\/j.psym.2020.05.006","journal-title":"Psychosomatics"},{"key":"ref42","article-title":"Prescription Drug Monitoring Program","author":"D'Souza RS","year":"2021","unstructured":"D'Souza RS, Lang M, Eldrige JS. Prescription Drug Monitoring Program. StatPearls, Treasure Island; 2021."},{"key":"ref43","unstructured":"Careful Prescribing of Benzodiazepines during COVID-19 Pandemic. A Review. (2020). Accessed: October 12, 2020: https:\/\/www.mentalhealthjournal.org\/articles\/careful-prescribing-of-benzodiazepines-during-covid-19-pandemic-a-review...."},{"key":"ref44","unstructured":"The TEDS Report. Substance Abuse Treatment Admissions for Abuse of Benzodiazepines. (2011). Accessed: June 2, 2011: https:\/\/atforum.com\/documents\/TEDS028BenzoAdmissions.pdf."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2016.05.120","article-title":"Benzodiazepine use, misuse, and abuse: a review","volume":"6","author":"Schmitz A","year":"2016","unstructured":"Schmitz A. Benzodiazepine use, misuse, and abuse: a review. Ment Health Clin. 2016, 6:120-6. 10.9740\/mhc.2016.05.120","journal-title":"Ment Health Clin"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103237","article-title":"Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: a national qualitative assessment in Canada","author":"Ali F","year":"2021","unstructured":"Ali F, Russell C, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: a national qualitative assessment in Canada. Int J Drug Policy. 2021, 103237. 10.1016\/j.drugpo.2021.103237","journal-title":"Int J Drug Policy"},{"key":"ref47","unstructured":"Drug-related deaths and deaths among drug users in Ireland. 2004-2014. (2017). Accessed: June 7, 2017: https:\/\/www.hrb.ie\/fileadmin\/publications_files\/Drugnet61_HRB_site.pdf."},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.090784","article-title":"Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone","volume":"181","author":"Dhalla IA","year":"2009","unstructured":"Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ. 2009, 181:891-6. 10.1503\/cmaj.090784","journal-title":"CMAJ"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102966","article-title":"Harm reduction in the time of COVID- 19: case study of homelessness and drug use in Dublin, Ireland","volume":"87","author":"O\u2019Carroll A","year":"2021","unstructured":"O\u2019Carroll A, Duffin T, Collins J. Harm reduction in the time of COVID- 19: case study of homelessness and drug use in Dublin, Ireland. Int J Drug Pol. 2021, 87:10.1016\/j.drugpo.2020.102966","journal-title":"Int J Drug Pol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2020.06.006","article-title":"Addictovigilance contribution during COVID-19 epidemic and lockdown in France","volume":"75","author":"Lapeyre-Mestre M","year":"2020","unstructured":"Lapeyre-Mestre M, Boucher A, Daveluy A, et al.. Addictovigilance contribution during COVID-19 epidemic and lockdown in France. Therapie. 2020, 75:343-54. 10.1016\/j.therap.2020.06.006","journal-title":"Therapie"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13187","article-title":"The impact of nationwide alcohol ban during the COVID-19 lockdown on alcohol use-related internet searches and behaviour in India: an infodemiology study","author":"Singh S","year":"2020","unstructured":"Singh S, Sharma P, Balhara YPS. The impact of nationwide alcohol ban during the COVID-19 lockdown on alcohol use-related internet searches and behaviour in India: an infodemiology study. Drug Alcohol Rev. 2020, 10.1111\/dar.13187","journal-title":"Drug Alcohol Rev"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1017\/ipm.2020.47","article-title":"Addiction psychiatry and COVID-19: impact on patients and service provision","volume":"37","author":"Columb D","year":"2020","unstructured":"Columb D, Hussain R, O'Gara C. Addiction psychiatry and COVID-19: impact on patients and service provision. Ir J Psychol Med. 2020, 37:164-8. 10.1017\/ipm.2020.47","journal-title":"Ir J Psychol Med"},{"key":"ref53","unstructured":"Non-medical use of benzodiazepines. a growing threat to public health?. (2017). Accessed: September 2017: https:\/\/www.unodc.org\/documents\/scientific\/Global_SMART_Update_2017_Vol_18.pdf."},{"key":"ref54","unstructured":"The misuse of benzodiazepines among high-risk opioid users in Europe. (2018). Accessed. June 7, 2018: https:\/\/www.emcdda.europa.eu\/topics\/pods\/benzodiazepines_en."},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2020.06.003","article-title":"Impact of COVID-19 related policy changes on filling of opioid and benzodiazepine medications","volume":"17","author":"Downs CG","year":"2021","unstructured":"Downs CG, Varisco TJ, Bapat SS, Shen C, Thornton JD. Impact of COVID-19 related policy changes on filling of opioid and benzodiazepine medications. Res Social Adm Pharm. 2021, 17:2005-8. 10.1016\/j.sapharm.2020.06.003","journal-title":"Res Social Adm Pharm"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1089\/pop.2020.0230","article-title":"The opioid epidemic within the COVID-19 pandemic: drug testing in 2020","volume":"24","author":"Niles JK","year":"2021","unstructured":"Niles JK, Gudin J, Radcliff J, Kaufman HW. The opioid epidemic within the COVID-19 pandemic: drug testing in 2020. Popul Health Manag. 2021, 24:S43-51. 10.1089\/pop.2020.0230","journal-title":"Popul Health Manag"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1089\/pop.2020.0230","article-title":"The opioid epidemic within the COVID-19 pandemic: drug testing in 2020","volume":"24","author":"Niles JK","year":"2021","unstructured":"Niles JK, Gudin J, Radcliff J, Kaufman HW. The opioid epidemic within the COVID-19 pandemic: drug testing in 2020. Popul Health Manag. 2021, 24:S43-51. 10.1089\/pop.2020.0230","journal-title":"Popul Health Manag"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18041967","article-title":"Changes in drug use patterns during the COVID-19 pandemic in Italy: monitoring a vulnerable group by hair analysis","volume":"18","author":"Gili A","year":"2021","unstructured":"Gili A, Bacci M, Aroni K, Nicoletti A, Gambelunghe A, Mercurio I, Gambelunghe C. Changes in drug use patterns during the COVID-19 pandemic in Italy: monitoring a vulnerable group by hair analysis. Int J Environ Res Public Health. 2021, 18:10.3390\/ijerph18041967","journal-title":"Int J Environ Res Public Health"},{"key":"ref59","unstructured":"Italian Medicines Agency. Report on drug use during the COVID-19 outbreak. (2020). Accessed. July 29, 2020: https:\/\/www.aifa.gov.it\/-\/uso-dei-farmaci-durante-l-epidemia-covid-19-il-29-luglio-la-presentazione-del-rapporto-aifa.."},{"key":"ref60","unstructured":"Global Medicine Spending and Usage Trends. Outlook to 2025.. (2021). Accessed: 28 April 2021: https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/global-medicine-spending-and-usage-trends-outlook-to-2025.."},{"key":"ref61","article-title":"Trends in pharmacotherapy for anxiety and depression during COVID- 19: a North York area pilot study","volume":"98","author":"Yu C","year":"2021","unstructured":"Yu C, Boone C, Askarian-Monavvari R, Brown T. Trends in pharmacotherapy for anxiety and depression during COVID- 19: a North York area pilot study. Un Toronto Med J. 2021, 98:41-46.","journal-title":"Un Toronto Med J"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.575755","article-title":"The impact of COVID-19 pandemic on the Castile and Leon Addiction Treatment Network: a real-word experience","volume":"11","author":"Roncero C","year":"2020","unstructured":"Roncero C, Vicente-Hern\u00e1ndez B, Casado-Espada NM, et al.. The impact of COVID-19 pandemic on the Castile and Leon Addiction Treatment Network: a real-word experience. Front Psychiatry. 2020, 11:575755. 10.3389\/fpsyt.2020.575755","journal-title":"Front Psychiatry"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100504","article-title":"Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system","volume":"26","author":"McCarthy CP","year":"2020","unstructured":"McCarthy CP, Murphy S, Jones-O'Connor M, et al.. Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system. EClinicalMedicine. 2020, 26:100504. 10.1016\/j.eclinm.2020.100504","journal-title":"EClinicalMedicine"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/60414-benzodiazepine-misuse-an-epidemic-within-a-pandemic","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T14:25:29Z","timestamp":1707488729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/60414-benzodiazepine-misuse-an-epidemic-within-a-pandemic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":63,"URL":"https:\/\/doi.org\/10.7759\/cureus.15816","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,21]]}}}